title: New kind of antiretroviral, KP-1461; clinical trial recruiting. Interview with Stephen Becker, M.D.
abstract: KP-1461, an experimental HIV drug already in a phase II trial, works so differently from other antiretrovirals that at first glance it looked like science fiction, and we found it hard to take seriously as a current possibility today. In fact this drug is highly credible, and based on elegant science that goes back at least 25 years. KP-1461 is the only antiretroviral in human use or testing that can eradicate HIV from laboratory cell cultures. No one knows how it will work in people -- but we might know by the second quarter of 2008, when the current phase II trial could be complete. AIDS Treatment News interviewed Dr. Stephen Becker, a leading AIDS physician and researcher who is vice president of clinical development at Koronis Pharmaceuticals, in Seattle, Washington.
authors.forename: Stephen
authors.initials: S
authors.lastname: Becker
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D009705:Nucleosides / Q000627:therapeutic use*
chemical_list: D019380:Anti-HIV Agents; C522536:KP 1461; D009705:Nucleosides